(124 days)
Not Found
Not Found
No
The description details a mechanical and optical method for detecting blood clotting time, with no mention of AI or ML algorithms for data processing or result interpretation.
No.
Explanation: The device is described as an "in vitro diagnostic device" that provides quantitative prothrombin time (PT) results and is specifically for monitoring patients on warfarin therapy, not for delivering a therapeutic intervention.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states, "The Immedia System is an in vitro diagnostic device." The device description further elaborates on its function to provide quantitative prothrombin time (PT) results and monitor patients on warfarin therapy, which are diagnostic purposes.
No
The device description clearly outlines hardware components such as a meter, test strips, a rotating wheel, infrared light beam, and batteries/AC adapter. It is a physical device that performs a test using these components.
Yes, the provided text explicitly states that the Immedia System is an IVD (In Vitro Diagnostic) device.
The "Intended Use / Indications for Use" section begins with: "The Immedia System is an in vitro diagnostic device..."
N/A
Intended Use / Indications for Use
The Immedia System is an in vitro diagnostic device that provides quantitative prothrombin time (PT) results, expressed in seconds and INR units. It uses fresh capillary whole blood. It is intended for use by health care professional at the point of care to monitor patients who are on warfarin-type (coumarin) anticoagulation therapy. The device is not intended to be used for screening purposes.
Product codes (comma separated list FDA assigned to the subject device)
JPA
Device Description
The Immedia™ Prothrombin Time System measures the Prothrombin Time (PT) of fresh capillary whole blood. The test is performed by inserting a test strip into the meter and applying a drop of blood to the sample receptacle of the test strip. The meter automatically performs the PT test and the result is displayed as International Normalized Ratio (INR) and seconds (PT). The meter automatically stores all test results in memory. The device is powered by batteries and/or AC adapter. The disposable strip contains a rotating, spoked wheel that draws the sample into the reaction well after it is applied to the sample receptacle. The spokes rotate across the path of an infrared light beam and mix the liquid sample with the thromboplastin which is dried in the reaction well. When the sample clots, the clot is picked up by the spokes, interrupting the path of the infrared light beam that is detected by the meter. A separate Calibration Strip is used for inputting the calibration data. High Control and Low Control Strips are also provided for quality control purposes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
health care professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The accuracy of the Immedia device was compared to the CoaguChek S and a reference method in field studies and found to be equivalent (r>0.90). Precision and linearity evaluations were performed on the Immedia device and the results were found to be acceptable. Additional testing on interfering substances, and hematocrit were performed and the results are reflected in the product labeling
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
The Roche CoaguChek® system, CoaguChek S®
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.5425 Multipurpose system for in vitro coagulation studies.
(a)
Identification. A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.(b)
Classification. Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
0
JUN 6 - 2005
PREMARKET NOTIFICATION 510(k) Summary
According to the requirements of 21 CFR 807.92 the following information provides sufficient detail to understand the basis for determination of substantial equivalence
Farallon Medical Inc. 3521 Investment Blvd., Suite 1 Hayward, CA 94545 Phone: 510-785-0800 FAX: 510-785-0888
Contact person: Mr. James McKinley
Date Prepared: January 31, 2005
-
- Device name:
-
- Predicate device:
-
- Device description:
Device Name: Immedia Prothrombin Time System Proprietary/Trade Name: Immedia Prothrombin Time System Common Name: Prothrombin Time Test
The Roche CoaguChek® system: Device for testing Prothrombin Time and INR in whole blood.
The Immedia™ Prothrombin Time System measures the Prothrombin Time (PT) of fresh capillary whole blood. The test is performed by inserting a test strip into the meter and applying a drop of blood to the sample receptacle of the test strip. The meter automatically performs the PT test and the result is displayed as International Normalized Ratio (INR) and seconds (PT). The meter automatically stores all test results in memory. The device is powered by batteries and/or AC adapter. The disposable strip contains a rotating, spoked wheel that draws the sample into the reaction well after it is applied to the sample receptacle. The spokes rotate across the path of an infrared light beam and mix the liquid sample with the thromboplastin which is dried in the reaction well. When the sample clots, the clot is picked up by the spokes, interrupting the path of the infrared light beam that is detected by the meter. A separate Calibration Strip is used for inputting the calibration data. High Control and Low Control Strips are also provided for quality control purposes.
Introduction
- Submitter's name,
address, contact:
3
1
- The Immedia system is an in vitro diagnostics system that 5. Intended use: provides a quantitative ProthrombinTime test result for fresh capillary whole blood expressed in seconds and an international normalized ratio (INR). It is intended for use by health care professionals in monitoring patients who are on warfarin-type (coumarin) anticoagulation therapy. This device is not intended to be used for screening purposes. The Immedia system is substantially equivalent in design, 6. Comparison to materials and intended use to other products that measure Predicate device Prothrombin Time in human blood. Most notably, it is substantially equivalent to the CoaguChek S®, manufactured by Roche Diagnostics. The accuracy of the Immedia device was compared to the 7. Summary of CoaguChek S and a reference method in field studies and performance data found to be equivalent (r>0.90). Precision and linearity evaluations were performed on the Immedia device and the results were found to be acceptable. Additional testing on
interfering substances, and hematocrit were performed and
the results are reflected in the product labeling
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three heads facing to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
JUN 6 - 2005
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. James McKinley President and CEO Farallon Medical, Inc. 3521 Investement Boulevard Suite 1 Hayward, California 94545
Re: K050243 Trade/Device Name: Immedia Prothrombin Time System Regulation Number: 21 CFR § 864.5425 Regulation Name: System, multipurpose for in vitro coagulation studies Regulatory Class: II Product Code: JPA Dated: May 2, 2005 Received: May 3, 2005
Dear Mr. McKinley:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
3
Page 2 –
If you desire specific information about the application of labeling requirements to your device, IT you desire specific information as advertising of your device, please contact the Office of In of questions on the promotion and Safety at (240) 276-0484. Also, please note the Vitto Diagnostic Doved Drailand in reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the I bu may obtain of Schorar monitational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html
Sincerely yours,
lobatz Beckeyh
Robert L. Becker, Jr., MD, PA Director Division of Immunology and Hematology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known):_____________________________________________________________________________________________________________________________________________________ K050243
Immedia Prothrombin Time System Device Name: _________________________________________________________________________________________________________________________________________________________________
The Immedia System is an in vitro diagnostic device that provides Indications For Use: quantitative prothrombin time (PT) results, expressed in seconds and INR units. It uses fresh capillary whole blood. It is intended for use by health care professional at the point of care to monitor patients who are on warfarin-type (coumarin) anticoagulation therapy. The device is not intended to be used for screening purposes.
Stephanic Bautista
Division/Sign Off
Office of In Vitro Diagnostic Device
Evaluation and Safety
510(k) -
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)